{
  "metadata": {
    "case_id": 57,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T17:13:24.769865",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/57_NCT01781637.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/57_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.72,
          0.15
        ],
        [
          0.05,
          0.6
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.72,
          "status": "matched",
          "ref_item": {
            "label": "omalizumab group",
            "type": "EXPERIMENTAL",
            "description": "Patients will receive omalizumab.",
            "interventionNames": [
              "Drug: Omalizumab"
            ]
          },
          "pred_item": {
            "label": "Omalizumab + Peanut OIT",
            "type": "EXPERIMENTAL",
            "description": "Subjects received omalizumab for 12 weeks followed by rapid escalation of peanut protein (OIT) to 250 mg on the first day of desensitization, then weekly up-dosing to 2000 mg. Omalizumab was continued for a total of 19 weeks, then discontinued while OIT continued.",
            "interventionNames": [
              "Biological: Omalizumab",
              "Biological: Peanut Oral Immunotherapy (OIT)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.6,
          "status": "matched",
          "ref_item": {
            "label": "placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients will receive placebo.",
            "interventionNames": [
              "Drug: placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo + Peanut OIT",
            "type": "PLACEBO_COMPARATOR",
            "description": "Subjects received placebo for 12 weeks followed by rapid escalation of peanut protein (OIT) to 250 mg on the first day of desensitization, then weekly up-dosing to 2000 mg. Placebo was continued for a total of 19 weeks. Subjects failing to reach the 250 mg dose were given the option to switch to open-label omalizumab.",
            "interventionNames": [
              "Other: Placebo",
              "Biological: Peanut Oral Immunotherapy (OIT)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.92,
          0.2,
          0.3
        ],
        [
          0.2,
          0.78,
          0.2
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Omalizumab",
            "description": "subcutaneous injection",
            "armGroupLabels": [
              "omalizumab group"
            ],
            "otherNames": [
              "Xolair"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "Omalizumab",
            "description": "Anti-IgE antibody administered for 12 weeks prior to desensitization and continued for a total of 19 weeks.",
            "armGroupLabels": [
              "Omalizumab + Peanut OIT"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "placebo",
            "description": "subcutaneous injection",
            "armGroupLabels": [
              "placebo"
            ]
          },
          "pred_item": {
            "type": "OTHER",
            "name": "Placebo",
            "description": "Placebo matching omalizumab administered for 12 weeks prior to desensitization and continued for a total of 19 weeks.",
            "armGroupLabels": [
              "Placebo + Peanut OIT"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.2
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.2,
          "status": "matched",
          "ref_item": {
            "measure": "Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo",
            "timeFrame": "6 weeks after last dose of omalizumab/placebo"
          },
          "pred_item": {
            "measure": "Peanut-specific IgE and IgG epitope binding profiles",
            "description": "Profiling of antibody responses to peanut peptides using AllerScan (phage immunoprecipitation sequencing). Enrichment of peptides is quantified as Z-scores based on sequencing read counts compared to mock immunoprecipitation controls.",
            "timeFrame": "Week 0 and Week 52"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.1,
          0.04
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.1,
          "status": "matched",
          "ref_item": {
            "measure": "Pass 4000 mg OFC 12 Weeks After Last Dose of Omalizumab/Placebo",
            "timeFrame": "12 weeks after last dose of omalizumab/placebo"
          },
          "pred_item": {
            "measure": "Antibody repertoire breadth",
            "description": "The number of wild-type peanut peptides recognized by IgE and IgG antibodies per individual, used to evaluate the diversity of the antibody response.",
            "timeFrame": "Week 0 and Week 52"
          }
        }
      ]
    }
  ]
}